Skip to main content
. 2022 Dec 5;10(12):2078. doi: 10.3390/vaccines10122078

Figure 2.

Figure 2

Dose-dependent immunogenicity and efficacy of LbL-MP loaded with RSV GM2 epitopes. BALB/c mice were immunized on days 0 and 21 with the indicated doses of GM2 LbL-MP, challenged with RSV on day 35, and sacrificed for plaque assay on day 40. (A) Day 28 post-boost serum antibody titers measured by RSV G protein ELISA. Endpoint titers of individual mice (open circles) and group means (bars). * p < 0.05 compared to naïve. (B) Day 28 spleen cell ELISPOTs restimulated in vitro with a pool of M281–95 and G169–198 peptides. Mean ± SEM spots/106 cells of 3 mice/group. * p < 0.05 compared to naïve for both analytes by t-test. (C) Lung viral titers 5 days post-challenge. Number of plaques per gram of lung tissue for individual mice (circles) and group means (bars). Insets show number of mice with no detectable plaques (n = 12 mice per group), average % reduction in plaques per group, and * p < 0.05 compared to the naïve group.